Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

Interview: High renal response without renal decline supports the safety and efficacy of lenalidomide doses higher than recommended during induction in transplant-eligible newly diagnosed multiple myeloma patients, explains Frida Bugge Askeland, Consultant Physician, Oslo Myeloma Center, Oslo University Hospital, Norway.